A Genotype-Phenotype Urothelial Cancer Registry
Overview
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Enrollment
- 3,519
- Locations
- 4
- Primary Endpoint
- Determine whether single nucleotide polymorphisms in regions discovered from whole genome scans, such as 8q24 & chromosome 3, & candidate genes, include NAT2 & GSTM1, prev found to be assoc with bladder ca risk, are assoc with UC in this study population
Overview
Brief Summary
This study is being done to create a registry to help us learn more about urinary and other cancers. This will let us look at large groups of people who do and do not have this kind of cancer.
The investigators will look at risk factors to learn more about how these impact cancer. The investigators will also look at genetic markers. These are genes that are found in a known place. They are often associated with a particular trait. If the gene changes in some way, it may predict cancer or response to treatment. The investigators will look for markers in your saliva.
This registry will help us develop better methods of:
Preventing these cancers. Diagnosing these cancers. Treating these cancers.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Urothelial Cancer Cases
- •Must be ≥ 18 years of age AND
- •Must have a diagnosis of urothelial cancer AND
- •Must be an English-speaker
- •Non-Cancer Control Group
- •Must be ≥ 18 years of age AND
- •Must not have cancer or a personal history of cancer, with the exception of skin cancer. AND
- •Must not be a blood relative of cases AND
- •Must not be a blood relative of another control AND
- •Must be an English-speaker
Exclusion Criteria
- •Have any condition, which in the opinion of the primary MSKCC clinician or investigators precludes their ability to provide informed consent.
Outcomes
Primary Outcomes
Determine whether single nucleotide polymorphisms in regions discovered from whole genome scans, such as 8q24 & chromosome 3, & candidate genes, include NAT2 & GSTM1, prev found to be assoc with bladder ca risk, are assoc with UC in this study population
Time Frame: 2 years
Secondary Outcomes
- To determine whether single nucleotide polymorphisms in the genes and regions listed above are associated with outcomes after UC diagnosis in the population(2 years)